6 unknown, 5 recruiting, 3 active not recruiting, 3 not yet recruiting. 17 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Unknown 6, Recruiting 5, Active not recruiting 3, Not yet recruiting 3 |
| Phase 1 | 3 | Unknown 2, Not yet recruiting 1 |
| Phase 3 | 2 | Recruiting 1, Unknown 1 |
Follow Immune Checkpoint Inhibitors: new trials by email Literature Review of Immune Checkpoint Inhibitors trials Research Report on Immune Checkpoint Inhibitors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response lattice radiation therapy - Locally Advanced Non-small Cell Lung Cancer (NSCLC), Thoracic Radiotherapy | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2026-07-01 | 2026-06-26 |
| Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDS Sintilimab - HIV, AIDS | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Public Health Clinical Center | 50 | 2026-05-01 | 2026-05-12 |
| Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy QL1706 combined with Chemotherapy - Breast Cancer, Neoadjuvant Therapy | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 40 | 2026-04-14 | 2026-09-28 |
| Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer Disitamab Vedotin, Lenvatinib, Pembrolizumab - Biliary Tract Cancer, Disitamab Vedotin | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 65 | 2025-08-30 | 2025-09-08 |
| Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2) Durvalumab, Methotrexate, Vinblastine - Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors | Phase 2 | Recruiting | AstraZeneca | 150 | 2025-05-15 | 2026-10-08 |
| Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC Sintilimab - Non-Small Cell Lung Cancer, Adjuvant Therapy | Phase 2 | Recruiting | Sichuan University | 100 | 2025-01-10 | 2026-08-05 |
| Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer Electroacupuncture combined with immunotherapy, Zilongjin tablet combined with immunotherapy, Immunotherapy - Non-Small Cell Lung Cancer, Electroacupuncture | Phase 2 / Phase 3 | Recruiting | Kong Fanming | 405 | 2025-01-01 | 2025-06-24 |
| Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma Fruquintinib - Hepatocellular Carcinoma, Immune Checkpoint Inhibitors | Phase 2 | Recruiting | Sun Yat-sen University | 36 | 2024-12-27 | 2024-12-31 |
| Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction Serplulimab Combined With Chemotherapy, Placebo combined with Chemotherapy - Stomach Neoplasms, Immune Checkpoint Inhibitors | Phase 2 | Active not recruiting | Xijing Hospital | 116 | 2024-11-15 | 2026-10-26 |
| Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Toripalimab, Cytoreductive Nephrectomy, Axitinib - Immune Checkpoint Inhibitors, Cytoreductive Nephrectomy | Phase 2 | Active not recruiting | RenJi Hospital | 21 | 2024-03-01 | 2026-10-27 |
| Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer Tislelizumab, Oxaliplatin, Capecitabine - Colonic Neoplasms, Neoadjuvant Therapy | Phase 2 | Active not recruiting | First Affiliated Hospital of Guangxi Medical University | 60 | 2023-11-13 | 2025-09-24 |
| Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma Cadonilimab, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitors | Phase 1 / Phase 2 | Unknown | Guangxi Medical University | 20 | 2023-08-01 | 2023-06-12 |
| Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Cadonilimab, Stereotactic radiotherapy, Renvatinib - Hepatocellular Carcinoma Non-resectable, Portal Vein Tumor Thrombus | Phase 1 / Phase 2 | Unknown | First Affiliated Hospital of Guangxi Medical University | 30 | 2023-02-02 | 2023-09-15 |
| The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors - Gemcitabine, Biliary Tract Cancer | Phase 2 / Phase 3 | Unknown | First People's Hospital of Hangzhou | 50 | 2022-08-01 | 2022-08-04 |
| Tislelizumab and Radiotherapy for Recurrent Cervical Cancer Tislelizumab plus radiotherapy - Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma | Phase 2 | Unknown | Lei Li | 58 | 2022-03-27 | 2022-04-11 |
| Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial Anti-PD-1 antibody camrelizumab, Albumin-bound paclitaxel - Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma | Phase 2 | Unknown | Lei Li | 122 | 2022-03-13 | 2022-03-22 |
| A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs). Camrelizumab combined Apatinib regimen - Hepatocellular Carcinoma, Immune Checkpoint Inhibitors | Phase 2 | Unknown | Hunan Cancer Hospital | 40 | 2021-02-03 | 2021-04-01 |
Carcinoma, Hepatocellular (3) · Biliary Tract Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Uterine Cervical Neoplasms (2) · Acquired Immunodeficiency Syndrome (1) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Nasopharyngeal Carcinoma (1) · Opportunistic Infections (1) · Stomach Neoplasms (1) · Urinary Bladder Neoplasms (1)
Neoplasms (15) · Neoplasms by Site (15) · Digestive System Diseases (7) · Digestive System Neoplasms (7) · Carcinoma (5) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Urogenital Diseases (5) · Adenocarcinoma (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Urogenital Neoplasms (4) · Genital Diseases (3) · Liver Diseases (3) · Liver Neoplasms (3)
Cisplatin (2) · Drug Therapy (2) · Gemcitabine (2) · Oxaliplatin (2) · Surgical Procedures, Operative (2) · sintilimab (2) · tislelizumab (2) · toripalimab (2) · Albumin-Bound Paclitaxel (1) · Axitinib (1) · Capecitabine (1) · Colectomy (1) · Doxorubicin (1) · HMPL-013 (1) · Immunotherapy (1)
First Affiliated Hospital of Guangxi Medical University (2) · Lei Li (2) · Tianjin Medical University Cancer Institute and Hospital (2) · AstraZeneca (1) · First People's Hospital of Hangzhou (1) · Guangxi Medical University (1) · Hunan Cancer Hospital (1) · Kong Fanming (1) · Peking Union Medical College Hospital (1) · RenJi Hospital (1) · Shanghai Public Health Clinical Center (1) · Sichuan University (1) · Sun Yat-sen University (1) · Xijing Hospital (1)
China (15) · Australia (1) · Brazil (1) · Canada (1) · France (1) · Italy (1) · Netherlands (1) · Spain (1)
Lei Li, M.D. (2) · Jun Zhang (1) · Liu Hong, Ph.D (1) · Sen Zhang (1) · Yongsheng Jia (1)
PMID 10581077, PMID 11556297, PMID 15928658, PMID 21365500, PMID 21444866, PMID 22189752, PMID 23664139, PMID 24514954, PMID 24618998, PMID 24662266, PMID 24889903, PMID 25943068, PMID 26412280, PMID 26808342, PMID 27156933, PMID 28102259, PMID 28457713, PMID 28622514, PMID 29370182, PMID 29961579, PMID 30479382, PMID 30566590, PMID 30911859, PMID 32861308, PMID 41293180, PMID 42682622